| 000 | 01824 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515092934.0 | ||
| 264 | 0 | _c20080219 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a1600-6143 | ||
| 024 | 7 |
_a10.1111/j.1600-6143.2007.02031.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReischig, T | |
| 245 | 0 | 0 |
_aValacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. _h[electronic resource] |
| 260 |
_bAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons _cJan 2008 |
||
| 300 |
_a69-77 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcyclovir _xanalogs & derivatives |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 | _aCytomegalovirus |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xeconomics |
| 650 | 0 | 4 |
_aCzech Republic _xepidemiology |
| 650 | 0 | 4 |
_aGanciclovir _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aValacyclovir |
| 650 | 0 | 4 | _aValganciclovir |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 700 | 1 | _aJindra, P | |
| 700 | 1 | _aHes, O | |
| 700 | 1 | _aSvecová, M | |
| 700 | 1 | _aKlaboch, J | |
| 700 | 1 | _aTreska, V | |
| 773 | 0 |
_tAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons _gvol. 8 _gno. 1 _gp. 69-77 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1600-6143.2007.02031.x _zAvailable from publisher's website |
| 999 |
_c17492453 _d17492453 |
||